Masaoka Ⅱ期胸腺瘤患者完整手术切除后辅助放疗的疗效及预后分析

Therapeutic efficacy and prognostic analysis of adjuvant radiotherapy after complete resection of thymoma in Masaoka stage Ⅱ patients

目的探讨MasaokaⅡ期胸腺瘤患者完整手术切除后辅助放疗的临床效果及预后情况。方法回顾性分析65例MasaokaⅡ期胸腺瘤患者的临床资料。根据患者术后是否接受辅助放疗将患者分为对照组(接受单纯手术治疗,n=43)和观察组(术后接受辅助放疗,n=22)。采用Kaplan-Meier法绘制两组患者的生存曲线,组间比较采用Log-rank检验。结果观察组患者的3年累积生存率为90.91%(20/22),对照组患者的3年累积生存率为86.05%(37/43),两组比较,差异无统计学意义(P﹥0.05)。观察组患者的无进展生存率为90.91%,高于对照组患者的72.09%,差异有统计学意义(P﹤0.05)。放疗后,观察组共有3例患者发生不良反应,占13.64%(3/22)。结论MasaokaⅡ期胸腺瘤患者完整手术切除后进行辅助放疗虽然不能提高患者的总生存率,但可以提高患者的无进展生存率,且术后辅助放疗后,患者发生的不良反应较少。

Objective To study the therapeutic efficacy and prognostic analysis of adjuvant radiotherapy after complete resection of thymoma in Masaoka stage II patients. Method Sixty-five patients with stage II thymoma were collected and analyzed retrospectively. The patients were divided into two groups： the control group（operation only, n=43） and the observation group（operation followed by postoperative adjuvant radiotherapy, n=22）. The survival curve was drawn by KaplanMeier method and the differences between the two groups were compared by the Log-rank test. Result The 3-year cumulative survival rate in the observation group was 90.91%（20/22）, and 86.05%（37/43） in the control group, without significant difference between the two groups（P〉0.05）. The progression-free survival rate of the observation group was 90.91%,which was significantly higher than that of the control group as 72.09%（P〈0.05）. There were adverse reactions after radiotherapy occurred in 3 cases（13.64%） in the observation group. Conclusion The adjuvant radiotherapy after complete surgical resection for Masaoka stage II thymoma can not increase the survival rate of patients, but can significantly improve the progression-free survival rate. The adverse reactions of adjuvant radiotherapy patients were relatively low.